Predictive value of intratumoral 99mTc-macroaggregated albumin uptake in patients with colorectal liver metastases scheduled for radioembolization with 90Y-microspheres

Journal of Nuclear Medicine

Volumn 54, Issue 4, 2013, Pages 516-522

  Ulrich, Gerhard ^a   Dudeck, Oliver ^a   Furth, Christian ^a   Ruf, Juri ^a   Grosser, Oliver S ^a   Adolf, Daniela ^a   Stiebler, Marvin ^a   Ricke, Jens ^a   Amthauer, Holger ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

Perfusion scintigraphy; Radioembolization; Response prediction; SIRspheres

Indexed keywords

MACROSALB TC 99M; MICROSPHERE; RESIN; YTTRIUM 90;

ADULT; AGED; ARTICLE; ARTIFICIAL EMBOLISM; CANCER GROWTH; CLINICAL EVALUATION; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; HUMAN; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTIVE VALUE; PRIORITY JOURNAL; RADIOEMBOLIZATION; TREATMENT RESPONSE; TUMOR VOLUME;

ADULT; AGED; BIOLOGICAL TRANSPORT; COLORECTAL NEOPLASMS; EMBOLIZATION, THERAPEUTIC; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MICROSPHERES; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; TECHNETIUM TC 99M AGGREGATED ALBUMIN; TREATMENT OUTCOME; TUMOR BURDEN; YTTRIUM RADIOISOTOPES;

EID: 84875801677     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.112.112508     Document Type: Article

References (37)

1. Geschwind JFH, Salem R, Carr BI, et al. Yttrium-90 microspheres for the treatment of hepatocellular carcinoma. Gastroenterology. 2004;127(suppl):S194- S205.
2. Jakobs TF, Hoffmann R, Poepperl G, et al. Mid-term results in otherwise treatment refractory primary or secondary liver confined tumours treated with selective internal radiation therapy (SIRT) using 90yttrium resin-microspheres. Eur Radiol. 2007;17:1320-1330.
3. Sato KT, Lewandowski RJ, Mulcahy MF, et al. Unresectable chemorefractory liver metastases: radioembolization with 90Y microspheres-safety, efficacy, and survival. Radiology. 2008;247:507-515.
4. Kennedy AS, Salem R. Radioembolization (yttrium-90 microspheres) for primary and metastatic hepatic malignancies. Cancer J. 2010;16:163-175.
5. Murthy R, Nunez R, Szklaruk J, et al. Yttrium-90 microsphere therapy for hepatic malignancy: devices, indications, technical considerations, and potential complications. Radiographics. 2005;25(suppl 1):S41-S52.
6. Gray B, van Hazel G, Hope M, et al. Randomised trial of SIR-Spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol. 2001;12:1711-1720.
7. Ho S, Lau WY, Leung TW, et al. Partition model for estimating radiation doses from yttrium-90 microspheres in treating hepatic tumours. Eur J Nucl Med. 1996;23:947-952.
8. 99mTclabelled macroaggregated albumin (MAA) scintigraphy for planning treatment with 90Y microspheres. Eur J Nucl Med Mol Imaging. 2010;37:2328-2333.
9. 99mTc-MAA in radioembolization with 90Y microspheres in patients with hepatocellular cancer. J Nucl Med. 2009;50:688-692.
10. Ahmadzadehfar H, Biersack H, Ezziddin S. Radioembolization of liver tumors with yttrium-90 microspheres. Semin Nucl Med. 2010;40:105-121.
11. Denecke T, Hildebrandt B, Lehmkuhl L, et al. Fusion imaging using a hybrid SPECT-CT camera improves port perfusion scintigraphy for control of hepatic arterial infusion of chemotherapy in colorectal cancer patients. Eur J Nucl Med Mol Imaging. 2005;32:1003-1010.
12. Daly JM, Butler J, Kemeny N, et al. Predicting tumor response in patients with colorectal hepatic metastases. Ann Surg. 1985;202:384-393.
13. Lehner B, Kretzschmar U, Bubeck B, Hölting T, Schlag P. Results of liver angiography and perfusion scintigraphy do not correlate with response to hepatic artery infusion chemotherapy. J Surg Oncol. 1988;39:73-78.
14. Civalleri D, Scopinaro G, Balletto N, et al. Changes in vascularity of liver tumours after hepatic arterial embolization with degradable starch microspheres. Br J Surg. 1989;76:699-703.
15. Flamen P, Vanderlinden B, Delatte P, et al. Multimodality imaging can predict the metabolic response of unresectable colorectal liver metastases to radioembolization therapy with yttrium-90 labeled resin microspheres. Phys Med Biol. 2008;53:6591-6603.
16. 99mTc-MAA) uptake by colorectal liver metastases to response following selective internal radiation therapy (SIRT). BMC Nucl Med. 2005;5:7-16.
17. Hudson HM, Larkin RS. Accelerated image reconstruction using ordered subsets of projection data. IEEE Trans Med Imaging. 1994;13:601-609.
18. Chang LT. A method for attenuation correction in radionuclide computed tomography. IEEE Trans Nucl Sci. 1978;25:638-643.
19. Minarik D, Sjögreen Gleisner K, Ljungberg M. Evaluation of quantitative 90Y SPECT based on experimental phantom studies. Phys Med Biol. 2008;53: 5689-5703.
20. Grober OS, Nultsch M, Laatz K, et al. Radioembolization with 90Y-labeled microspheres: post-therapeutic therapy validation with bremsstrahlung-SPECT. Z Med Phys. 2011;21:274-280.
21. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45: 228-247.
22. Breedis C, Young G. The blood supply of neoplasms in the liver. Am J Pathol. 1954;30:969-977.
23. Llovet JM, Real MI, Montaña X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359:1734-1739.
24. Kennedy AS, Nutting C, Coldwell D, Gaiser J, Drachenberg C. Pathologic response and microdosimetry of 90Y microspheres in man: review of four explanted whole livers. Int J Radiat Oncol Biol Phys. 2004;60:1552-1563.
25. Dudeck O, Zeile M, Wybranski C, et al. Early prediction of anticancer effects with diffusion-weighted MR imaging in patients with colorectal liver metastases following selective internal radiotherapy. Eur Radiol. 2010;20:2699-2706.
26. Folkman J. How is blood vessel growth regulated in normal and neoplastic tissue? G.H.A. Clowes memorial award lecture. Cancer Res. 1986;46:467-473.
27. Holash J, Maisonpierre PC, Compton D, et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science. 1999;284: 1994-1998.
28. Rajaganeshan R, Prasad R, Guillou PJ, et al. The influence of invasive growth pattern and microvessel density on prognosis in colorectal cancer and colorectal liver metastases. Br J Cancer. 2007;96:1112-1117.
29. Mooteri S, Rubin D, Leurgans S, Jakate S, Drab E, Saclarides T. Tumor angiogenesis in primary and metastatic colorectal cancers. Dis Colon Rectum. 1996;39:1073-1080.
30. Sato KT, Omary RA, Takehana C, et al. The role of tumor vascularity in predicting survival after yttrium-90 radioembolization for liver metastases. J Vasc Interv Radiol. 2009;20:1564-1569.
31. Campbell AM, Bailey IH, Burton MA. Tumour dosimetry in human liver following hepatic yttrium-90 microsphere therapy. Phys Med Biol. 2001;46: 487-498.
32. Campbell AM, Bailey IH, Burton MA. Analysis of the distribution of intraarterial microspheres in human liver following hepatic yttrium-90 microsphere therapy. Phys Med Biol. 2000;45:1023-1033.
33. Burton MA, Gray BN, Klemp PF, Kelleher DK, Hardy N. Selective internal radiation therapy: distribution of radiation in the liver. Eur J Cancer Clin Oncol. 1989;25:1487-1491.
34. Rühl R, Seidensticker M, Peters N, et al. Hepatocellular carcinoma and liver cirrhosis: assessment of the liver function after yttrium-90 radioembolization with resin 21 microspheres or after CT-guided high-dose-rate brachytherapy. Dig Dis. 2009;27:189-199.
35. 99m Tc-macroaggregated albumin SPECT/CT accurately predicts tumor response and survival in hepatocellular carcinoma patients treated with 90Y-loaded glass microspheres: preliminary results. J Nucl Med. 2012;53:255-263.
36. 18FDG-PET: a comparison with CT or MRI. Eur J Nucl Med Mol Imaging. 2002;29:815-820.
37. 18F-FDG PET/CT predicts survival after radioembolization of hepatic metastases from breast cancer. J Nucl Med. 2012;53:371-377.